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 Sinergismo vs antagonismo  
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Goals of Antibiotic therapy 
To kill the infecting bacteria 
• Decrease inflamation 
• Reduce the inoculum 
• Prevent resistance 
 
Importance of adequacy – MIC and PK/PD 
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Alvarez-Lerma ICM 1996;22:387 Rello. AJRCCM 1997;156:196 
Kollef Chest. 1998;113:412 Kollef Chest. 1999; 115:462 
Ibrahim Chest. 2000;118:146 Luna. Chest. 1997;111:676 
Leroy ICM 2003;29:2170 Póvoal ERJ 2005;25:804 
Garnacho-Montero JAC 2008;61:436 
Initial antibiotic therapy and 
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Causes of Antibiotic Failure 
– Inappropriate antibiotics 
– Delay of antibiotic therapy 
– Multiple organ failure 
– Inoculum 
– Insufficient dose 
– Biofilms 
Can the Antibiotic Strategy be design to further 
improve patient outcome? – Combining antibiotics 
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Surviving Sepsis Guidelines 
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Advantages / Disadvantages 
Achieve broader cover for the empiric therapy 
Treatment of mixed infections 
Prevention of the development of resistance 
Reduce toxicity 
Achieve antibacterial sinergysm 
Antagonism – drug to drug interaction 
Adverse events 
Development of  antimicrobial resistance 
Increased costs 
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If risk factors for Listeria monocytogenes: 
 
• Age > 50 years or < 2 months 
• Diabetes 
• Alchoolism 
• Immunosupression 
• Malignancy 
Bacterial Meningitis 
3rd Gen Cephalosporin + Ampicillin 
Tunkel AR et al. CID 2004; 39 :1267-1284 
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Peritonite  
B. fragilis group 
E. coli 
Clostridium spp. 
Klebsiella spp. 
Streptococcus spp. 
Enterococcus spp. 
Pseudomonas spp. 
 
E. coli 
Klebsiella spp. 
Streptococcus spp. 
Enterococcus spp. 
Outros bacilos Gram-
negativos 
Secundária (Polimicrobiana) Primária (Monomicrobiana) 
Barie PS. J Chemother. 1999;11:464-477. 
LaRoche M, Harding G. Eur J Clin Microbiol Infect Dis. 1998;17:542-550. 
S. anginosus 
©Copyright 2005 gbf.de / All rights reserved 
B. fragilis 
E. coli 
©Copyright 2005 cmsp.com / All rights reserved ©Copyright 2005 cmsp.com / All rights reserved ©Copyright 2005 cmsp.com / All rights reserved 
Enterococci 
Pseudomonas 
S. epidermidis 
Candida 
Terciária (Polimicrobiana) 
S. epidermidis 
Cefalosporina 3ª G 
Fluoroquinolona 
Cefoxitina 
Moxifloxacina 
Tigeciclina 
Amoxicilina Clavulanato 
Ertapenem 
Cefalosporina de 2ª ou 3ª G + 
Metronidazol 
Fluoroquinolona + Metronidazol 
Peritonite Secundária Grave 
Piperacilina Tazobactam 
Carbapenem 
Cefalospo ina d  3ª ou 4ª G + 
Metronidazol 
Ciprofloxacina + Metronidazol 
 
Terapêutica combinada 
de acordo com as 
etiologias identificadas / 
prováveis 
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Abdominal Infections 
Bochud PY et al. Crit Care Med 2004; 32:S495-512 
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Community-Acquired Pneumonia 
AUTHOR POPULATION TYPE Nº 
COMBO 
SUPERIOR 
Gleason CAP Retro 12945 Yes 
Mufson, 1999 Bact. Pneumo Retro 328 Yes 
Waterer, 2001 Bact. Pneumo Retro 225 Yes 
Martinez, 2003 Bact. Pneumo Retro 409 Yes 
Weiss, 2004 Bact. Pneumo Retro 95 Yes 
Harbarth 
Pneumococcal 
sepsis 
Retro 107 No 
Garcia-Vasquez CAP Retro 1391 Yes 
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Prospective observational cohort study of 529 adults with severe 
CAP 
Combination antibiotic therapy seems to increase ICU survival in 
patients with severe CAP and  shock 
Rodriguez A (CAPUCI group) Crit Care Med 2007; 35: 1493 
p = 0.99 
OR = 1.69 95% CI 1.09 –2.60 
p=  0.01 
Even when monotherapy was appropriate, it achieved a lower 28-day 
survival than an adequate antibiotic combination OR 1,64 (1,01-2,64) 
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Ventilator Associated Pneumonia 
AJRCCM 2005; 171: 388-416 
ATS GUIDELINES 
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N=174 N=129 
Single drug for Gram Negative infections – 154 
No coverage of MRSA - 24 
 Compliance with ATS/IDSA Guidelines 
Ventilator Associated Pneumonia  
Combination therapy 
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Paul. BMJ 2004; doi:10.1136/bmj.38028.520995.63 
No advantage of 
combination therapy 
• Gram negative 
infections (N=1835) 
• Pseudomonas 
aeruginosa (N=426) 
 
Ventilator Associated Pneumonia  
Combination therapy 
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Meta-analysis of 62 eligible datasets 
OR (death/clinical failure) 
0.856 (95% CI, 0.713–1.027) 
    (p= 0.094)  
Combination therapy demonstrates a 
significant advantage over 
monotherapy when the rate of 
death/clinical failure exceeds 25% 
OR 0.54; 95% CI, 0.45– 0.66  (p = 0.0001) 
Kumar A et al. Crit Care Medicine 2010; 38 :1651-1654 
Sepsis 
Combination therapy 
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Sepsis 
Combination therapy 
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Synergism 
“In vitro” for many antibiotic combinations 
 
 
Calandra T et al. Am J Med 1986; 80: 45. Kumar A et al. ICAAC Proc 2004; 26: A-1296; 
Darras-Joly C et al. Antimicrob Agents Chemother 1996; 40: 2147; 
Giamarellou H. Am J Med 1986; 80: 126. Giamarellou H et al. Antimicrob Agents Chemother 1984; 25: 534. 
 
Anderson ET et al. Chemotherapy 1978;24(1):45–54. Bouza E et al. Med Clin North Am 
2000;84(6):1357–89; 
De Jongh CA et al. Am J Med 1986;80(5C):96–100. 
• Clinical studies of infection (including endocarditis, Gram 
negative bacteremia and neutropenic infections) 
 
• Specific types of infection: 
– HIV 
– Tuberculosis 
– Helicobacter pylori 
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Synergism of antibiotics (In vitro)  
Ab 1 + 2 
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Ab 2 
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Decrease 
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The Lab 
 
 
Use of measured antibiotic 
concentrations administered at 
precise time points and tested 
against a standard inoculum of 
bacteria 
Real Life 
Antibiotic concentrations in the 
host is determined by: 
– dose, volume distribution and 
elimination rate of atb  
– patient’s age, volume status, 
weight, renal and hepatic 
function, hypoalbuminemia 
– site of infection 
Bacterial load is highly variable 
Is clinical proof necessary? 
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Endocarditis 
Leibovici L International Journal of Antimicrobial Agents 2010; 36S: S46–S49 
Mortality 
OR 0.44 95% CI 0.12-1.58 
Bacteriological Failure 
OR 0.89 95% CI 0.47-1.69 
Clinical Failure 
OR 0.69 95% CI 0.40-1.19 
Jo
ão
 G
.P
ereira 
Time (hours) 
L
o
g
1
0
 C
F
U
/
m
L
 
Antagonism of antibiotics (In vitro)  
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Inhibition of the target synthesis by 
the weakest antibiotic 
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Pseudomonas aeruginosa 
Acinetobacter baumannii 
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Broaden the antimicrobial 
spectrum 
Synergism 
Decrease 
emergence of antimicrobial 
resistance 
Minimize superinfection 
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In vitro synergism 
Wide ranges of results 
Dependent on several methodological factors: 
  - method of synergy test used 
  - susceptibility patterns of the isolates 
  - concentrations of antibiotics used 
The greatest likelihood of synergy is an aminoglycoside with an 
antipseudomonal penicillin (~ 90%), and then, in decreasing order, with 
a cephalosporin (~ 80%) or a carbapenem (~ 50%).  
 
The interaction of fluoroquinolones combined with β-lactams or 
aminoglycosides was usually autonomous (additive) or indifferent.  
For quinolone combinations plus antipseudomonal β-lactams, the β-
lactam drug accomplished most of the bacterial killing. 
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Ps aeruginosa Bacteremia 
The absence of septic shock at the time of 
bacteremia (AOR 0.07; 95% CI, 0.01-0.49; p = 0.008), 
and combination therapy (AOR 0.05; 95% CI 0.01-
0.34; p = 0.002) as variables that were independently 
associated with decreased all-cause 28-day mortality 
No significant difference in terms of the emergence of 
antimicrobial resistance (21.9% and 12.1% respectively; p 
= 0.29). 
 
However, the 2-week bacteria eradication rate (54.5% vs. 
18.8%, p = 0.04) and the 4-week eradication rate (54.5% vs. 
28.1%, p = 0.04) were significantly higher in the combination 
therapy group than the monotherapy group. 
Park et al. BMC Infectious Diseases 2012, 12:308 
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Ps aeruginosa VAP 
•  Retrospective, observational, cohort study 
•  183 episodes of monomicrobial P. 
aeruginosa VAP 
• Initial use of combination therapy significantly reduces the likelihood of 
inappropriate therapy, which is associated with higher risk of death. 
• However, administration of only one effective antimicrobial or 
combination therapy provides similar outcomes, suggesting that 
switching to monotherapy once the susceptibility is documented is 
feasible and safe. 
Garnacho-Montero J Crit Care Med 2007; 35: 1888 
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In vitro synergism 
Colistin Tigecycline Carbapenems Sulbactam Aminoglyc Rifampicin Others 
Colistin + + + Pipt/tazo 
Tigecycline + + + 
Carbapenems + + + 
Sulbactam + 
Cefepime 
Fosfomycin 
• Colistin + Tigecycline: better with Tigecycline 200 mg q12h 
• Colistin + Carbapenem: 
– In vitro synergy rates of 77% (95% CI: 64 to 87%) 
– Meropenem was more synergistic than imipenem 
• Carbapenem + Aminoglycoside: probably no better than carbapenem 
(imipenem) monotherapy 
• Carbapenem + Rifampicin: no clinical benefit 
• Triple combination therapy of meropenem,sulbactam and colistin has 
consistently shown very high levels of synergy. 
Acinetobacter baumannii 
Jo
ão
 G
.P
ereira 
Carbapenemase-producing Kl. 
pneumoniae 
Daikos GL et al AAC 2009; 53: 1868-1873 
% 
n= 67 cases 
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Carbapenemase-producing 
Kl. pneumoniae 
Qureshi ZA et al. AAC 2012; 56: 2108-2113 
The 28-day mortality was 13.3% in the CT vs. 57.8% in the M group (P = 0.01).  
In the multivariate analysis, definitive therapy with a combination regimen 
was independently associated with survival (OR 0.07 ;95% CI 0.009-0.71; p = 
0.02).  
Despite in vitro susceptibility, patients who received monotherapy with colistin-polymyxin B or 
tigecycline had a higher mortality of 66.7%.  
Colistin/Tigecycline + carbapenem: most common (mortality - 12.5%). 
Zarkotou O et al. CMI 2011; 17: 1798-1803 
• Overall mortality was 52.8% and infection mortality was 34% 
• Appropriate antimicrobial therapy was administered to 35 patients (66%) 
• In the appropriate group: mortality in CT was significantly lower than in M group (0% vs. 
46,7%; p= 0.001) 
• In univariate analysis, combinations of active antimicrobials (p 0.001) were 
significantly associated with survival. 
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Resistance induction: Optimisation 
of minimum concentration/MIC ratio 
T>MIC=100%  Cmin/MIC=1.7+ tobramycin 
Placebo 
T>MIC=84% 
T>MIC=100% & Cmin/MIC=10 
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Tam Antimicrob Agents Chemother 2005; 49. 4920 
Wild type 
Amp C mutant 
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"I see no hope for the future of our people if they are 
dependent on the frivolous youth of today, for they are 
reckless beyond words. When I was young, we were taught to 
be discreet, respectful of elders, but the present youth are 
exceedingly disrespectful and impatient."  
   Hesiod, 700 BC 
